Announced
Completed
Financials
Tags
Private
Biotechnology
biotechnology
Private Equity
United States
Acquisition
Domestic
Friendly
Minority
Single Bidder
Venture Capital
Completed
Synopsis
Redmile Group, a hedge fund and private equity manager, led a $150m Series D funding round in Mammoth Biosciences, a biotech company. Additional investors included Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX and Plum Alley. “We’ve had a momentous year at Mammoth, which includes the maturation of our wholly-owned CRISPR platform for breakthrough therapeutic applications and partnerships with industry leaders that have accelerated the validation of our diagnostic technology in the real world,” Trevor Martin, Mammoth Biosciences Co-Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.